CHG SCRUB (chlorhexidine gluconate) by Johnson & Johnson is clinical pharmacology periogard® (chlorhexidine gluconate oral rinse usp, 0. First approved in 1986.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
CHG SCRUB (Chlorhexidine Gluconate) is a topical antimicrobial oral rinse solution approved by FDA in 1986 that reduces oral bacteria by 54-97% through broad-spectrum activity against aerobic and anaerobic plaque organisms. The drug works via retained oral cavity deposition (~30% of dose) with slow release into oral fluids, maintaining local antimicrobial effect without significant systemic absorption or bacterial resistance development. It is used for oral hygiene and plaque control in dental and clinical settings.
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling potential team consolidation and transition focus toward market defense and generic transition planning.
CLINICAL PHARMACOLOGY PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate oral rinse's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general…
Worked on CHG SCRUB at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
CHG SCRUB offers limited career growth due to zero linked job openings, mature lifecycle stage, and approaching loss of exclusivity. Roles on this product typically involve defending market share against generics, managing price erosion, and optimizing operational efficiency rather than growth and innovation opportunities.